Early diagnosis of melanoma: What do we know?

Giornale Italiano di Dermatologia e Venereologia

Volumn 142, Issue 2, 2007, Pages 55-70

  Yee, E F T ^a,c   Hoffman, R M ^b   Berwick, M ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c Division of Epidemiology University of New Mexico Cancer Research Treatment Center ^*  (United States)

Author keywords

Melanoma, diagnosis; Melanoma, pathology; Skin neoplasms

Indexed keywords

CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; HEALTH EDUCATION; HUMAN; MELANOMA; MORTALITY; PATHOPHYSIOLOGY; REVIEW; SKIN EXAMINATION;

EID: 34250800296     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, et al. Malignant melanoma in the 21st century, part 1: Epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007;82:364-80.
2. Austoker J. Melanoma: Prevention and early diagnosis. BMJ 1994;308:1682-6.
3. th, Epstein MN, Greene MH, Van Horn M. A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984; 15:1147-65.
4. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006; 355:51-65.
5. Burton RC, Armstrong BK. Current melanoma epidemic: A nonmetastasizing form of melanoma? World J Surg 1995;19:330-3.
6. Halpern AC, Lieb JA. Early melanoma diagnosis: A success story that leaves room for improvement. Curr Opin Oncol 2007;19:109-15.
7. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004;150:179-85.
8. Marks R. Epidemiology of melanoma. Clin Exp Dermatol 2000; 25:459-63.
9. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146 Suppl 61:1-6.
10. Armstrong BK, Kricker A. Cutaneous melanoma. Cancer Surv 1994; 19-20:219-40.
11. Garbe C, McLeod GR, Buettner PG. Time trends of cutaneous melanoma in queensland, australia and central europe. Cancer 2000; 89:1269-78.
12. World Health Organization. GLOBOCAN: Cancer Incidence, Mortality, and Prevalence Worldwide, IARC Cancerbase No.5, Version 1.0. Lyon:IARC Press, 2001.
13. th edition. Canada: Quality Medical Publishing; 2003.p.15-23.
14. th edition. Canada: Quality Medical Publishing, Inc.; 2003.p.93-120.
15. Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Johansson H, Ringborg U. Trends in mortality from malignant melanoma in sweden, 1970-1996. Cancer 2000;89:348-55.
16. Giles GG, Armstrong BK, Burton RC, Staples MP, Thursfield VJ. Has mortality from melanoma stopped rising in australia? analysis of trends between 1931 and 1994. BMJ 1996;312:1121-5.
17. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ et al. SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER web site 2006. http://www.seer.cancer.gov/ statfacts/html/melan.html?statfacts_page=melan.html&x=10&y=18. Accessed 3-1-07.
18. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). SEER*Stat Database:Incidence-SEER 17 Regs Public-use, Nov 2005 Sub (1973-2003 Varyingi), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.
19. Helfand M, Mahon SM, Eden KB, Frame PS, Orleans CT. Screening for skin cancer. Am J Prev Med 2001; 20:47-58. 20. Koh HK. Melanoma screening: Focusing the public health journey. Arch Dermatol 2007;143:101-3.
20. Coory M, Baade P, Aitken J, Smithers M, McLeod GR, Ring I. Trends for in situ and invasive melanoma in queensland, australia, 1982-2002. Cancer Causes Control 2006;17:21-7.
21. Edman RL, Klaus SN. Is routine screening for melanoma a benign practice? JAMA 2000;284:883-6.
22. Lamberg L. "Epidemic" of malignant melanoma: True increase or better detection? JAMA 2002;287:2201.
23. Swerlick RA, Chen S. The melanoma epidemic: More apparent than real? Mayo Clin Proc 1997;72:559-64.
24. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: Population based ecological study. BMJ 2005;331:481.
25. Swerlick RA, Chen S. The melanoma epidemic, is increased surveillance the solution or the problem? Arch Dermatol 1996;132:881-4.
26. Farmer ER. The fundamental issue of diagnosis. Arch Dermatol 2002;138:684-5.
27. Corona R, Mele A, Amini M, De Rosa G, Coppola G, Piccardi P et al. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol 1996;14:1218-23.
28. Farmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol 1996; 27:528-31.
29. th, Schuchter L, Ming M et al. Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. Arch Dermatol 2002;138:617-21.
30. Qin J, Berwick M, Ashbolt R, Dwyer T. Quantifying the change of melanoma incidence by breslow thickness. Biometrics 2002;58:665-70.
31. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C et al. Meta-analysis of risk factors for cutaneous melanoma: III. family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41:2040-59.
32. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P et al. Meta-analysis of risk factors for cutaneous melanoma: II. sun exposure. Eur J Cancer 2005;41:45-60.
33. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P et al. Meta-analysis of risk factors for cutaneous melanoma: I. common and atypical naevi. Eur J Cancer 2005;41:28-44.
34. Williams HA, Fritschi L, Beauchamp C, Karris P. Evaluating the usefulness of self-reported risk factors in a skin cancer screening program. Melanoma Res 2006;16:341-5.
35. MacKie RM, Freudenberger T, Aitchison TC. Personal risk-factor chart for cutaneous melanoma. Lancet 1989; 2:487-90.
36. Fears TR, Guerry D,4th, Pfeiffer RM, Sagebiel RW, Elder DE, Halpern A et al. Identifying individuals at high risk of melanoma: A practical predictor of absolute risk. J Clin Oncol 2006;24:3590-6.
37. Schuchter L, Schultz DJ, Synnestvedt M, Trock BJ, Guerry D, Elder DE et al. A prognostic model for predicting 10-year survival in patients with primary melanoma, the pigmented lesion group. Ann Intern Med 1996;125:369-75.
38. Margolis DJ, Halpern AC, Rebbeck T, Schuchter L, Barnhill RL, Fine J et al. Validation of a melanoma prognostic model. Arch Dermatol 1998;134:1597-601.
39. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the american joint committee on cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
40. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG et al. Final version of the american joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
41. Azzola MF, Shaw HM, Thompson JF, Soong SJ, Scolyer RA, Watson GF et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: An analysis of 3661 patients from a single center. Cancer 2003;97:1488-98.
42. Barnhill RL, Katzen J, Spatz A, Fine J, Berwick M. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol 2005;32:268-73.
43. Lange JR, Balch CM. Screening for cutaneous melanoma. Surg Oncol Clin N Am 2005;14:799-811.
44. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
45. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: The role of physician examination and self-examination of the skin. CA Cancer J Clin 1985;35:130-51.
46. Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I, et al. Early diagnosis of cutaneous melanoma: Revisiting the ABCD criteria. JAMA 2004;292:2771-6.
47. Grob JJ, Bonerandi JJ. The "ugly duckling" sign: Identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol 1998;134:103-4.
48. Fisher NM, Schaffer JV, Berwick M, Bolognia JL. Breslow depth of cutaneous melanoma: Impact of factors related to surveillance of the skin, including prior skin biopsies and family history of melanoma. J Am Acad Dermatol 2005;53:393-406.
49. Rigel DS, Friedman RJ, Kopf AW, Weltman R, Prioleau PG, Safai B et al. Importance of complete cutaneous examination for the detection of malignant melanoma. J Am Acad Dermatol 1986;14:857-60.
50. Lee G, Massa MC, Welykyj S, Choo J, Greaney V. Yield from total skin examination and effectiveness of skin cancer awareness program, findings in 874 new dermatology patients. Cancer 1991;67:202-5.
51. McPherson M, Elwood M, English DR, Baade PD, Youl PH, Aitken JF. Presentation and detection of invasive melanoma in a high-risk population. J Am Acad Dermatol 2006;54:783-92.
52. Epstein DS, Lange JR, Gruber SB, Mofid M, Koch SE. Is physician detection associated with thinner melanomas? JAMA 1999;281:640-3.
53. Schwartz JL, Wang TS, Hamilton TA, Lowe L, Sondak VK, Johnson TM. Thin primary cutaneous melanomas: Associated detection patterns, lesion characteristics, and patient characteristics. Cancer 2002;95:1562-8.
54. Brady MS, Oliveria SA, Christos PJ, Berwick M, Coit DG, Katz J et al. Patterns of detection in patients with cutaneous melanoma. Cancer 2000; 89:342-7.
55. Carli P, De Giorgi V, Palli D, Maurichi A, Mulas P, Orlandi C et al. Dermatologist detection and skin self-examination are associated with thinner melanomas: Results from a survey of the italian multidisciplinary group on melanoma. Arch Dermatol 2003;139:607-12.
56. Richard MA, Grob JJ, Avril MF, Delaunay M, Gouvernet J, Wolkenstein P et al. Delays in diagnosis and melanoma prognosis (II): The role of doctors. Int J Cancer 2000;89:280-5.
57. Thomas L, Tranchand P, Berard F, Secchi T, Colin C, Moulin G. Semiological value of ABCDE criteria in the diagnosis of cutaneous pigmented tumors. Dermatology 1998;197:11-7.
58. Healsmith MF, Bourke JF, Osborne JE, Graham-Brown RA. An evaluation of the revised seven-point checklist for the early diagnosis of cutaneous malignant melanoma. Br J Dermatol 1994;130:48-50.
59. McGovern TW, Litaker MS. Clinical predictors of malignant pigmented lesions. A comparison of the glasgow seven-point checklist and the american cancer society's ABCDs of pigmented lesions. J Dermatol Surg Oncol 1992;18:22-6.
60. Gachon J, Beaulieu P, Sei JF, Gouvernet J, Claudel JP, Lemaitre M et al. First prospective study of the recognition process of melanoma in dermatological practice. Arch Dermatol 2005;141:434-8.
61. Melia J, Harland C, Moss S, Eiser JR, Penary L. Feasibility of targeted early detection for melanoma: A population-based screening study. Br J Cancer 2000; 82:1605-9.
62. Roush GC, Barnhill RL, Ernstoff MS, Kirkwood JM. Inter-clinician agreement on the recognition of clinical pigmentary characteristics of patients with cutaneous malignant melanoma, studies of melanocytic nevi, VI. Br J Cancer 1991; 64:373-6.
63. Fritschi L, Dye SA, Katris P. Validity of melanoma diagnosis in a community-based screening program. Am J Epidemiol 2006;164:385-90.
64. Aitken JF, Elwood JM, Lowe JB, Firman DW, Balanda KP, Ring IT. A randomised trial of population screening for melanoma. J Med Screen 2002;9:33-7.
65. Aitken JF, Janda M, Elwood M, Youl PH, Ring IT, Lowe JB. Clinical outcomes from skin screening clinics within a community-based melanoma screening program. J Am Acad Dermatol 2006;54:105-14.
66. Swetter SM, Waddell BL, Vazquez MD, Khosravi VS. Increased effectiveness of targeted skin cancer screening in the veterans affairs population of northern California. Prev Med 2003;36:164-71.
67. Geller AC, Sober AJ, Zhang Z, Brooks DR, Miller DR, Halpern A et al. Strategies for improving melanoma education and screening for men age >or= 50 years: Findings from the american academy of dermatological national skin cancer sreening program. Cancer 2002;95:1554-61.
68. Engelberg D, Gallagher RP, Rivers JK. Follow-up and evaluation of skin cancer screening in british Columbia. J Am Acad Dermatol 1999;41:37-42.
69. Jonna BP, Delfino RJ, Newman WG, Tope WD. Positive predictive value for presumptive diagnoses of skin cancer and compliance with follow-up among patients attending a community screening program. Prev Med 1998;27:611-6.
70. Chen SC, Bravata DM, Weil E, Olkin I. A comparison of dermatologists' and primary care physicians' accuracy in diagnosing melanoma: A systematic review. Arch Dermatol 2001;137:1627-34.
71. Chen SC, Pennie ML, Kolm P, Warshaw EM, Weisberg EL, Brown KM et al. Diagnosing and managing cutaneous pigmented lesions: Primary care physicians versus dermatologists. J Gen Intern Med 2006;21:678-82.
72. Berwick M. Melanoma: Is more diagnosis better? J Gen Intern Med 2006; 21:800.
73. MacKie RM, Hole D. Audit of public education campaign to encourage earlier detection of malignant melanoma. BMJ 1992;304:1012-5.
74. Melia J. Early detection of cutaneous malignant melanoma in britain. Int J Epidemiol 1995;24 Suppl 1:S39-44.
75. Melia J, Cooper EJ, Frost T, Graham-Brown R, Hunter J, Marsden A et al. Cancer research campaign health education programme to promote the early detection of cutaneous malignant melanoma. II. characteristics and incidence of melanoma. Br J Dermatol 1995;132:414-21.
76. Whitehead SM, Wroughton MA, Elwood JM, Davison J, Stewart M. Effects of a health education campaign for the earlier diagnosis of melanoma. Br J Cancer 1989;60:421-5.
77. Graham-Brown RA, Osborne JE, London SP, Fletcher A, Shaw D, Williams B et al. The initial effects on workload and outcome of a public education campaign on early diagnosis and treatment of malignant melanoma in leicestershire. Br J Dermatol 1990; 122:53-9.
78. Herd RM, Cooper EJ, Hunter JA, McLaren K, Chetty U, Watson AC et al. Cutaneous malignant melanoma, publicity, screening clinics and survival - the edinburgh experience 1982-90. Br J Dermatol 1995;132:563-70.
79. Melia J, Moss S, Coleman D, Frost T, Graham-Brown R, Hunter JA et al. The relation between mortality from malignant melanoma and early detection in the cancer research campaign mole watcher study. Br J Cancer 2001;85:803-7.
80. US Preventive Services Task Force. Screening for skin cancer: Recommendations and rationale. Am J Prev Med 2001;20:44-6.
81. Weinstock MA. Early detection of melanoma. JAMA 2000;284:886-9.
82. Tornberg S, Mansson-Brahme E, Linden D, Ringborg U, Krakau I, Karnell R et al. Screening for cutaneous malignant melanoma: A feasibility study. J Med Screen 1996;3:211-5.
83. Karris P, Crock JG, Gray BN. Research note: The lions cancer institute and the western australian society of plastic surgeons skin cancer screening programme. Aust N Z J Surg 1996;66:101-4.
84. Weatherhead SC, Lawrence CM. Melanoma screening clinics: Are we detecting more melanomas or reassuring the worried well? Br J Dermatol 2006;154:539-41.
85. Veronesi A, Pizzichetta MA, De Giacomi C, Gatti A, Trevisan G, Regional Committee for the Early Diagnosis of Cutaneous Melanoma. A two-year regional program for the early detection of cutaneous melanoma. Tumori 2003;89:1-5.
86. Berwick M, Begg CB, Fine JA, Roush GC, Barnhill RL. Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst 1996;88:17-23.
87. Masri GD, Clark WH,Jr, Guerry D,4th, Halpern A, Thompson CJ, Elder DE. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol 1990;22:1042-8.
88. rd, Wolf LL, Gilchrest BA et al. Visual screening for malignant melanoma: A cost-effectiveness analysis. Arch Dermatol 2007;143:21-8.
89. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:1637-41.
90. Girgis A, Clarke P, Burton RC, Sanson-Fisher RW. Screening for melanoma by primary health care physicians: A cost-effectiveness analysis. J Med Screen 1996;3:47-53.
91. Freedberg KA, Geller AC, Miller DR, Lew RA, Koh HK. Screening for malignant melanoma: A cost-effectiveness analysis. J Am Acad Dermatol 1999;41:738-45.
92. Halpern AC, Lieb JA. Early melanoma diagnosis: A success story that leaves room for improvement. Curr Opin Oncol 2007;19:109-15.
93. Federman DG, Kravetz JD, Haskell SG, Ma F, Kirsner RS. Full-body skin examinations and the female veteran: Prevalence and perspective. Arch Dermatol 2006; 142:312-6.
94. Welch HG. Informed choice in cancer screening. JAMA 2001; 285:2776-8.
95. Berwick M. Evaluating early detection in the diagnosis of melanoma. Arch Dermatol 2006;142:1485-6.
96. Baade PD, English DR, Youl PH, McPherson M, Elwood JM, Aitken JF. The relationship between melanoma thickness and time to diagnosis in a large population-based study. Arch Dermatol 2006;142:1422-7.
97. Smith RA, Cokkinides V, Eyre HJ. American cancer society guidelines for the early detection of cancer, 2006. CA Cancer J Clin 2006;56:11-25; quiz 49-50.
98. Feightner JW. Prevention of skin cancer. Ottawa: Health Canada, 1994; In: Canadian Task Force on the Periodic Health Examination. Canadian Guide to Clinical Preventive Health Care. Ottawa: Health Canada; 1994.p.850-9.
99. Ferrini RL, Permian M, Hill L. American college of preventive medicine policy statement: Screening for skin cancer. Am J Prev Med 1998;14:80-2.
100. NIH consensus conference, diagnosis and treatment of early melanoma. JAMA 1992;268:1314-9.
101. Cancer Council Australia The Cancer Council of Australia 2004. National Cancer Prevention Policy 2004-06. NSW: The Cancer Council Australia. Available at: http://www.cancer.org.au/documents/NCPP_full_contents_links.pdf. Accessed March 30, 2007.
102. National Cancer Institute. Skin Cancer (PDQ) Screening: Health Professional Version http://www.cancer.gov/cancertopics/pdq/screening/skin/ HealthProfessional. Accessed March 30, 2007.
103. Field MJ, Lawrence RS, Zwanziger L, Eds., for the Institute of Medicine. Extending Medicare Coverage for preventive and other services. Washington D.C.: National Academy Press; 2000.